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lthough the pathophysiology of schizophrenia
remains unknown,clues about its mechanisms are emerg-
ing.
1 It is one of the most studied human illnesses in the
field of neuroscience.Moreover,the most sophisticated
modern techniques have been brought to bear on
answering its question: cellular and molecular tech-
niques,
2,3 genetics,
4 and in vivo imaging.
5We know that it
is a complex genetic illness with little gross pathology or
replicated markers of dysfunction.
Investigators in our laboratory,among others,have been
studying the localization of functional pathology in this
illness.In the future,this information will allow a more
detailed histological,cellular,and molecular examination
of changes in those target regions.Moreover,it will pro-
vide an experimental framework for future studies of
drug action and family studies.
Limbic cortex: the ACC and the HC
Our first suggestion that the limbic cortex could be a
player in the functional pathology of schizophrenia came
from the correlation that we identified between neuronal
activity in the anterior cingulate cortex (ACC) and hip-
pocampus (HC) (measured by [
18F]deoxyglucose positron
emission tomography) and the magnitude of psychosis
score (measured on the Brief Psychiatric Rating Scale
[BPRS]) (r=0.590;P=0.03).This correlation between psy-
chosis and neuronal activity was only obtained when the
study volunteers were drug-free,but was entirely obscured
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A
Studies on the pathophysiology of schizophrenia have
implicated the limbic cortex, using postmortem, structural,
and functional data, especially in the hippocampus (HC)
and the anterior cingulate cortex (ACC). We have made
contributions to the literature consistent with this idea:
first, we describe a positive significant correlation
between psychotic symptoms in schizophrenia and neu-
ronal activity in the ACC and HC, suggesting the involve-
ment of limbic cortex in the mediation of symptoms in
schizophrenia. Second, in the ACC and the anterior HC
(but not in the posterior HC), regional cerebral blood flow
(rCBF) is abnormal (ie, reduced in the ACC and elevated in
the HC) in schizophrenia. Third, the relationship of rCBF
to task difficulty in the ACC is altered in schizophrenia,
suggesting a failure of participation of the ACC in effort-
ful tasks. Lastly, connectivity between the ACC and HC
during the performance of an auditory discrimination task
is also lacking, suggesting that cognitive performance in
schizophrenia lacks a functional limbic contribution. On
the basis of these changes, we studied the effects of
antipsychotic drugs in these abnormal areas in persons
with schizophrenia. Both first- and second-generation
antipsychotics produce functional alterations in these lim-
bic cortical areas, in the direction of normals, putatively
acting through the brain’s own cortical-subcortical circuits.
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by antipsychotic medication.These findings suggest that
the symptoms of psychosis,in this case the positive symp-
toms, are mediated in some way by these brain areas.
Fortunately,this correlation between regional cerebral
blood flow (rCBF) and schizophrenia symptoms falls in
a brain region often noted to be abnormal in schizo-
phrenia,
5-8 increasing its face validity.
Moreover,in schizophrenia,the ACC and the HC show
altered levels of neuronal activity when at rest and when
performing a task relative to normals,so long as they are
in a medication-free condition.
9,10 During an auditory
recognition task, where performance was carefully
matched and the task trained between the schizophrenia
and the normal volunteers,the only area that showed a
significant difference from normal in task-activated neu-
ronal activity was the ACC.In this case,rCBF was lower
in the schizophrenia group.
11
Not only was the magnitude of activation reduced,but
also,in contrast to the normal volunteers,the activations
were irregularly related to performance.In the normal
group, there was a significant and positive correlation
between task difficulty and rCBF in the ACC,a region
critical to task performance. However, in the schizo-
phrenia group, there was no such relationship; in fact,
there was even a hint of an inverse correlation between
rCBF and the level of task difficulty (Figure 1).
The ACC lies on the medial surface of the frontal lobes,
and the HC is on the medial surface of the temporal lobe.
The HC is a small structure in terms of volume, but it
plays a critical role in human learning and memory.
12 In
schizophrenia,the function of this structure is abnormal
as measured by an increase in neuronal activity relative
to the normal volunteer in the anterior region only,with
the middle and posterior sections of the structure show-
ing normal rCBF.
10Again,this difference in schizophre-
nia only appears in the medication-free condition,since
treatment with an antipsychotic (either first- or second-
generation) reduced this abnormal rCBF in the anterior
HC.
13 Moreover,when probed with noncompetitive N-
methyl-D-aspartate (NMDA) blockade,specifically ket-
amine,rCBF in the HC was reduced,whereas no change
occurred with ketamine in normal volunteers (H. H.
Holcomb,manuscript in preparation).This observation
suggests that the hippocampal cortex in schizophrenia
may lack a normal NMDA-antagonism buffer,making
this region more susceptible to glutamate blockade at the
NMDA receptor in the illness.
Functional connectivity in the limbic cortex
The data so far suggest functional abnormalities in both
limbic cortical structures, the ACC and the HC. On the
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Response timebasis of these data,we hypothesize that the functional con-
nectivity between structures would be altered.Therefore,
we used a statistical technique called structural equation
modeling (SEM) to test the connectivity within limbic cor-
tex during the performance of an effortful task,an auditory
discrimination task.We used scans acquired from 12 nor-
mal volunteers and 18 volunteers with schizophrenia dur-
ing task performance and rest.First,by combining all scans
(ie,both groups) into a single analysis,we defined task-acti-
vated regions.Then,using an exploratory factor analysis,
we examined which regions showed a correlation with
each other.These data,plus the information already known
about connectivity with auditory cortex,were used to con-
struct an a priori hypothesized circuit (albeit simplified),
which could mediate the cerebral events associated with
task performance. We tested this hypothesized circuit
(Figure 2) for “activity”in mediating task performance in
the healthy volunteer group and in the schizophrenia
group (D.R.Medoff,manuscript in preparation).
In the normal volunteers,connectivity was evident between
the primary auditory cortex,forward through the thalamus
and to the middle frontal region, where most likely, the
short-term memory aspects of the task were mediated.
Also, the limbic cortex was significantly activated, con-
nected within itself,and connected to the thalamocortical
structures,to add a “top down”limbic component to the
performance of the discrimination task.However,within
the schizophrenia group,while there was evidence of an
effective pathway carrying the auditory information for-
ward through the thalamus to the middle frontal cortex,
the limbic component was missing.In schizophrenia,there
was no significant connectivity within the limbic cortex
(between the ACC and the HC) or between the limbic
structures and the thalamocortical regions mediating the
memory aspect of the task.Behaviorally,the group of vol-
unteers with schizophrenia were actually performing the
task equivalently to the normal volunteers,but apparently
without the added benefit of their limbic cortex.
These data suggest a failure of limbic activity in schizo-
phrenia to coordinate with neocortical activation for the
purpose of effortful task performance in schizophrenia.
These results suggest that persons with schizophrenia
accomplish effortful mental behaviors without the benefit
of normal limbic cortex activity,even when performing the
Pharmacological aspects
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behaviors equivalent to normals.This localization infor-
mation will allow us in future studies to develop a focus on
molecular and cellular abnormalities within these regions.
It is this ability to focus human postmortem studies on
brain regions likely to contain pathology that is one of the
values of this kind of localization information.Moreover,
we are proceeding to examine elements of the inhibitory
(GABAergic [GABA,γ-aminobutyric acid]) and excita-
tory (glutamatergic,especially NMDA-mediated) systems
in the limbic cortex in schizophrenia.
3
Effects of antipsychotic medication
This idea that functional pathology in schizophrenia can
be captured in altered limbic cortex function raises the
question of antipsychotic medication effects and the
regions in which those actions are manifest.With haloperi-
dol (the protypical first-generation antipsychotic), our
research showed that increases in neuronal activity in the
basal ganglia (caudate and putamen) and in the thalamus,
particularly the anterior portion, were associated with
haloperidol administration affecting the ACC and frontal
cortex first in what we interpreted as a tertiary action.
14
Regional decreases in neuronal activity were associated
with haloperidol in the ACC and in the frontal cortex,par-
ticularly the middle and the inferior portions.When we
evaluated clozapine (the prototypical second-generation
drug),we saw that the common areas of activation with
haloperidol were the caudate,the ventral striatum,and the
anterior thalamus, and the common areas of inhibition
were the HC and the ACC.
9These observations suggest
that antidopaminergic antipsychotic medications act
within the limbic and the limbic-related cortex to produce
their antipsychotic action,ie,in the very regions that are
dysfunctional in the disease itself.We have far to go in
explaining what the medications are actually doing in
these limbic regions (presumably, secondary to the
dopamine receptor blockade in the ventral striatum).In
addition to action in these common “antidopaminergic”
regions, we saw greater activation in frontal ACC and
medial frontal cortex with clozapine,perhaps accounting
for its superior antipsychotic actions.
The “systems” approach in schizophrenia
These results emphasize the “systems” aspect of patho-
physiology and therapeutics in schizophrenia.Schizophre-
nia is not merely an illness of a single brain region, and
probably not of any one neurotransmitter system.Rather,
in persons with the illness,it appears that an entire neural
system (in our hands,the limbic system) behaves abnor-
mally during mental tasks in association with disease
symptoms,and abnormally influences the related neocor-
tical and subcortical brain.It is the ACC and the HC that
seem to misfunction most regularly in psychotic states of
the illness,at rest,and with task stimulation.Without hav-
ing yet identified specifically where or what is the lesion,
it can be said that changes in neuronal activity in the lim-
bic pathways are associated with the symptoms of psy-
chosis and cognitive change.
We have carried out the number of studies with the dif-
ferent techniques described above to discover and eval-
uate the systems component of cerebral activation,and
compared normal and schizophrenia groups on rCBF
parameters.These approaches have led us to conclude
that limbic system function, especially around tasks of
learning and memory,is abnormal in schizophrenia.It is
our contention that treatments for the illness also should
be targeted toward a “system,”to correct the neuronal
activity of an entire “psychosis”system in schizophrenia.
The decades of research into the neural basis of
Parkinson’s disease has clarified much of the neural sub-
strate used by dopamine to exert its effects on frontal
cortex through the basal ganglia thalamocortical
(BGTC) circuits.
15 Studies in humans of the actions of
haloperidol on regional neuronal activity are consistent
with the idea that when antipsychotics act in striatum to
block the dopamine D2 receptors,a signal is transmitted
from the striatum,through the thalamus,to the frontal
cortex,including particularly the anterior cingulate and
the dorsolateral frontal.
14 It is in these areas of frontal
cortex where the full and final action of these antipsy-
chotic drugs is probably exerted on cortically mediated
human behaviors,but mediated through the BGTC cir-
cuit.Antipsychotics with additional monoaminergic and
other actions probably exert these actions directly in the
frontal cortex,in addition to the dopamine-mediated cir-
cuit actions.The latter extrastriatal effects may represent
an important difference between first- and second-gen-
eration antipsychotic drugs.
16
Dopamine and glutamate each appear to possibly have
preferential systems of influence: the frontal cortex-
BGTC circuit for dopamine and the limbic circuit for glu-
tamate.Especially the NMDA-sensitive glutamate recep-
tor, when blocked with a noncompetitive antagonist,
alters function primarily in limbic and frontal cortex (asmeasured by immediate early gene alterations in labo-
ratory rodents in response to phencyclidine
17 or by rCBF
alterations in humans in response to ketamine).
18Thus,
even if the initiation of this NMDA antagonist change is
in the limbic cortex,the extensive influence of the limbic
system on related neocortical and subcortical structures
is so potent that it alters function in frontal cortex and
even in the limbic striatum when hippocampal firing
changes.Thus, a convergent projection area of both of
these systems—the frontal neocortex and limbic cortex—
is common to both dopaminergic and NMDA-sensitive
glutamatergic transmission.Thus, while dopamine and
glutamate system pharmacologies are similar,each has
its preferential primary action systems and each delivers
its “information” to diverse brain regions in a highly
interactive/overlapping fashion, through the well-
described and existing neuronal circuits.
Conclusion
Schizophrenia is a disease of disordered mental produc-
tivity and organization,not of a single neurotoxic or neu-
rodegenerative pathogen,and,can be formulated entirely
as a neural systems disorder of the central nervous sys-
tem (CNS).This suggests that the function of the system
overall,not of any single component,may be abnormal
in the illness and could result in the symptoms of the ill-
ness.Thus,we have formulated our current antipsychotic
treatment actions as a systems approach to treating,not
necessarily the primary pathology of schizophrenia,but
the disordered system “output.”Because dopamine and
glutamate strongly modulate neural systems that have
overlapping tertiary targets (ie, the frontal cortex and
limbic striatum),the same kind of pharmacological action
(ie,“antipsychotic”) could be delivered to regions regu-
lating the behaviors of the CNS,be they motor,cognitive,
or affective, through, for example, the frontal cortex.
Thus, it is not only a drug action at a regional target
within the brain,but also,its overall action on a related
neural system in the brain that determines its overall
actions on neurally mediated behaviors and illnesses,like
schizophrenia.Known antipsychotic drugs that block D2
receptors likely have their therapeutic action on func-
tions of the frontal cortex,mediated through the BGTC
neuronal circuit.Psychotomimetic agents like ketamine
also appear to have their actions (antitherapeutic,in this
case) within the limbic cortex, but these actions also
extend into the frontal cortical regions.It would follow
then that neither of these drug effects seems to be
exerted primarily in the area of delivery,but as an indi-
rect projection effect to frontal cortex from different,but
overlapping,neuronal networks.The development and
testing of drugs that modulate the neuronal circuits of
interest for psychosis may provide novel approaches for
modulating neuronal activity in the frontal cortex and
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Estudios en esquizofrenia: fisiopatología y
tratamiento
Los estudios acerca de la fisiopatología de la esqui-
zofrenia utilizando datos postmortem, estructura-
les y funcionales han comprometido a la corteza
límbica, especialmente en el hipocampo (HC) y en
la corteza cingulada anterior (CCA). Nosotros
hemos realizado contribuciones a la literatura con-
sistentes con esta idea: primero, nosotros describi-
mos una correlación positiva significativa entre los
síntomas psicóticos de la esquizofrenia y la activi-
dad neuronal en la CCA y el HC, lo que sugiere el
compromiso de la corteza límbica en la mediación
de síntomas en la esquizofrenia. Segundo, en la
esquizofrenia el flujo sanguíneo cerebral regional
(FSCr) es anormal en la CCA y el HC anterior (pero
no en el HC posterior); está reducido en la CCA y
aumentado en el HC. Tercero, la relación entre la
dificultad para realizar una tarea y el FSCr en la CCA
se altera en la esquizofrenia, lo que sugiere una
falla en la participación de la CCA en las tareas de
gran esfuerzo. Finalmente, también existe una falta
de conexión entre la CCA y el HC durante la ejecu-
ción de una tarea de discriminación auditiva, lo que
sugiere que el rendimiento cognitivo en la esqui-
zofrenia adolece de una contribución funcional del
sistema límbico. En base a estos cambios, nosotros
estudiamos los efectos de fármacos antipsicóticos
en estas áreas anormales en personas con esquizo-
frenia. Tanto los antipsicóticos de primera como de
segunda generación producen alteraciones funcio-
nales en estas áreas de la corteza límbica, como
ocurre en los normales, al actuar putativamente a
través de los propios circuitos córtico-subcorticales
del cerebro.
Études sur la schizophrénie : 
physiopathologie et traitement
Les études sur la physiopathologie de la schizo-
phrénie ont impliqué le cortex limbique, sur la base
de données post mortem, structurales et fonction-
nelles, surtout dans l’hippocampe et le cortex cin-
gulaire antérieur (CCA). Nos contributions à la lit-
térature sont en accord avec cette notion :
premièrement, nous décrivons une corrélation posi-
tive significative entre les symptômes psychotiques
dans la schizophrénie et l’activité neuronale dans
l’hippocampe et le CCA, suggérant l’implication du
cortex limbique dans la médiation des symptômes
de la schizophrénie. Deuxièmement, dans le CCA et
l’hippocampe antérieur (mais pas dans l’hippo-
campe postérieur), le débit sanguin cérébral régio-
nal (DSCr) est anormal dans la schizophrénie (c'est-
à-dire, diminué dans le CCA et élevé dans
l’hippocampe). Troisièmement, la relation dans le
CCA entre le DSCr et la difficulté de la tâche est
altérée au cours de la schizophrénie, ce qui suggère
un déficit de participation du CCA dans les tâches
difficiles. Enfin, la connexion entre le CCA et l’hip-
pocampe au cours d’une tâche de discrimination
auditive est également absente, évoquant un
défaut de participation limbique fonctionnelle dans
la performance cognitive au cours de la schizo-
phrénie. Sur la base de ces modifications, nous
avons étudié les effets des antipsychotiques dans
ces zones anormales chez des schizophrènes. Les
antipsychotiques de première et de seconde géné-
ration entraînent tous deux des modifications fonc-
tionnelles dans ces zones corticales limbiques, s’ap-
prochant des résultats des sujets normaux, en
agissant, a priori, par l’intermédiaire des propres cir-
cuits cérébraux corticaux-sous-corticaux.